Publication
Randomized Prospective Comparison Between Neoadjuvant Mitomycin C Plus Cisplatin and Paclitaxel Plus Carboplatin in Patients With BRCA1-Associated Ovarian Cancer.
Tatiana V Gorodnova, Anna P Sokolenko, Khristina B Kotiv, Roman V Donskih, Maria G Yakovleva, Yuri N Trifanov, Svetlana N Aleksakhina, Natalia S Morozova, Ekaterina A Kolesnikova, Victoria O Smirnova, Alexey M Belyaev, Igor V Berlev, Evgeny N Imyanitov
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Neoadjuvant mitomycin C plus cisplatin (MP) previously demonstrated promising activity in high-grade serous ovarian cancer in a single-arm study of BRCA1 pathogenic variant (PV) carriers. This prospective, open-label, randomized Phase II trial (NCT04747717) compared MP with standard…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04747717registry_reference1.00
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Registered trialsNCT04747717
Curated evidence
Evidence citing this paper (0)
Data not yet available